The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Jul. 07, 2016
Applicants:

Accelerated Medical Diagnostics, Inc., Berkeley, CA (US);

Lawrence Livermore National Security, Llc, Livermore, CA (US);

The Regents of the University of California, Oakland, CA (US);

Inventors:

Paul Henderson, Berkeley, CA (US);

George D. Cimino, Lafayette, CA (US);

Chong-Xian Pan, Davis, CA (US);

Ralph William de Vere White, Sacramento, CA (US);

Maike Zimmermann, Davis, CA (US);

Kenneth W. Turteltaub, Livermore, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); G01N 33/53 (2006.01); G01N 33/60 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 31/28 (2006.01); A61K 31/395 (2006.01); G01N 33/68 (2006.01); G01N 33/96 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57484 (2013.01); A61K 31/28 (2013.01); A61K 31/395 (2013.01); A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); G01N 33/5308 (2013.01); G01N 33/60 (2013.01); G01N 33/6848 (2013.01); G01N 33/96 (2013.01); A61K 2300/00 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.


Find Patent Forward Citations

Loading…